SCHEMBL3877679

SCHEMBL3877679

C[C@H]1CN(c2nccnc2Cl)CCN1c1cc(-c2ccc(F)c(Cl)c2)nc(N2CCOCC2)n1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MTOR P42345 9/20 0.39
PIK3CA P42336 7/20 0.39
MAP3K12 Q12852 1/20 0.38
WDR5 P61964 1/20 0.38
KDM4E B2RXH2 2/20 0.37
LMNA P02545 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
MALT1 Q9UDY8 1/20 0.37
TRPV1 Q8NER1 1/20 0.37
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
HPGD P15428 1/20 0.36
TSHR P16473 1/20 0.36
CYP2C19 P33261 1/20 0.36
HSD17B10 Q99714 1/20 0.36
SYK P43405 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3877699 1.00 MTOR (0.39) MTORPIK3CAMAP3K12WDR5KDM4E
SCHEMBL3877815 0.94 MTOR (0.40) MTORPIK3CAMAP3K12KDM4ELMNA
SCHEMBL3881049 0.94 MTOR (0.40) MTORPIK3CAMAP3K12KDM4ELMNA
SCHEMBL13761564 0.94 MTOR (0.40) MTORPIK3CAMAP3K12KDM4ELMNA
SCHEMBL3879422 0.93 MTOR (0.41) MTORPIK3CAMAP3K12KDM4ELMNA
SCHEMBL3880822 0.93 MALT1 (0.38) MAP3K12KDM4EMALT1TRPV1HSD17B10
SCHEMBL3880508 0.93 MALT1 (0.38) MAP3K12KDM4EMALT1TRPV1HSD17B10
SCHEMBL3884807 0.92 MTOR (0.39) MTORPIK3CAMAP3K12WDR5KDM4E
SCHEMBL3879443 0.92 MTOR (0.44) MTORPIK3CA
SCHEMBL3879244 0.91 MTOR (0.39) MTORPIK3CAMAP3K12KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7566712-B2 Biaryl piperazinyl-pyridine analogues NEUROGEN CORPORATION (US) 2009-07-28 US disclosed
US-7566712-B2 Biaryl piperazinyl-pyridine analogues NEUROGEN CORPORATION (US) 2009-07-28 US disclosed
US-7566712-B2 Biaryl piperazinyl-pyridine analogues NEUROGEN CORPORATION (US) 2009-07-28 US disclosed
US-20070027155-A1 Biaryl piperazinyl-pyridine analogues NEUROGEN CORPORATION 2007-02-01 US disclosed
US-20070027155-A1 Biaryl piperazinyl-pyridine analogues NEUROGEN CORPORATION 2007-02-01 US disclosed
US-20070027155-A1 Biaryl piperazinyl-pyridine analogues NEUROGEN CORPORATION 2007-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027155-A1 Biaryl piperazinyl-pyridine analogues GPR174, GPR68, PPARG MTOR 2949/4885PIK3CA 1107/4885MAP3K12 2603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.